1. Introduction {#sec1}
===============

Muscarinic acetylcholine receptors (MRs) belong to the class A G-protein coupled receptor (GPCR) superfamily and comprise five receptor subtypes in humans (designated M~1~R--M~5~R).^[@ref1]−[@ref4]^ Whereas the M~1~R, M~3~R, and M~5~R receptors were reported to couple with G~q~ proteins, the M~2~R and M~4~R receptors bind to G~i/o~ proteins.^[@ref5]^ MRs represent interesting drug targets, for instance, for the treatment of Alzheimer's disease and schizophrenia.^[@ref6],[@ref7]^ Because of the high conservation of the orthosteric (acetylcholine) binding site,^[@ref8]−[@ref10]^ there is lack of highly subtype selective (orthosteric) ligands, hampering therapeutic approaches such as the treatment of cognitive decline by centrally acting selective M~1~R agonists or M~2~R antagonists.^[@ref11]^ However, in addition to the orthosteric binding pocket, MRs were reported to exhibit distinct allosteric binding sites, which are less conserved and can potentially be exploited to develop subtype selective ligands.^[@ref12]−[@ref17]^ The M~2~R was the first GPCR described to be subjected to allosteric modulation,^[@ref18]−[@ref20]^ and several dualsteric M~2~R ligands (e.g., **7**([@ref21]) and **10**,^[@ref22],[@ref23]^[Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A) and allosteric M~2~R modulators (e.g., **13**,^[@ref20]^**14**,^[@ref18]^ and **15**,^[@ref24],[@ref25]^[Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B) were identified.

![(A) Structures of the described MR agonists (ACh, CCh, **1**, and **2**) and antagonists (**3--10**). The M~2~R binding poses of compounds **7** and **10** were reported to overlap in part with the binding pose of allosteric M~2~R modulator **14**.^[@ref21],[@ref23]^ (B) Structures of the selected allosteric MR ligands (compounds **11--15**). (C) Structures of heterodimeric ligands **16** and **17** as well as homodimeric MR ligands **18** and **19**, the latter suggested to exhibit a dualsteric binding mode at the M~2~R.^[@ref23]^](ao-2017-01085p_0001){#fig1}

Dimerization of GPCR ligands can result in an increased receptor affinity and improved selectivity.^[@ref26],[@ref27]^ Bivalent (dimeric) ligands were described for various GPCRs, such as opioid,^[@ref28]^ histamine,^[@ref29],[@ref30]^ dopamine,^[@ref31]−[@ref33]^ adenosine,^[@ref33]−[@ref35]^ and neuropeptide Y^[@ref36]−[@ref38]^ receptors, not least to investigate receptor dimerization. Likewise, the design of dualsteric (bitopic) ligands, that is, hybrid derivatives that simultaneously address the orthosteric and allosteric sites of one and the same receptor protomer, represents an approach toward improved subtype selectivity.^[@ref19],[@ref39]−[@ref42]^ For example, rationally designed hybrid MR ligands derived from the orthosteric agonist oxotremorine (**2**) and hexamethonium-like allosteric modulators (e.g., compound **16**, [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}C) showed increased subtype selectivity compared to **2**.^[@ref43]^ Similarily, the MR ligand THRX-160209 (compound **17**, [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}C) was reported to exhibit a higher M~2~R affinity and selectivity than the corresponding monovalent ligands and was suggested to bind to the M~2~ receptor in a multivalent manner.^[@ref44]^

Pyridobenzodiazepinone derivative **7** and the structurally closely related dibenzodiazepinone derivative **8** ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A) represent tricyclic M~2~R-preferring MR antagonists.^[@ref45],[@ref46]^ Tränkle et al. suggested a dualsteric binding mode of **7** at the M~2~ receptor,^[@ref21]^ and a hybrid ligand formed of **7** and allosteric modulator **14** was reported to show a pronounced positive cooperativity with **5**, pointing at a new way for the development of allosteric enhancers.^[@ref47],[@ref48]^

This study was aimed at the design, synthesis, and pharmacological evaluation of heterodimeric MR ligands derived from **8**, comprising five combinations of **8** with reported orthosteric or allosteric MR ligands: "**8**--xanomeline (**1**)," "**8**--TBPB (**11**)," "**8**--77-LH-28-1 (**12**)," "**8**--4-DAMP (**3**)," and "**8**--propantheline (**4**)." Xanomeline (**1**) (cf. [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A) is a M~1~ and M~4~ receptor preferring MR agonist.^[@ref49]^ Compound **11** (cf. [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B) was reported to selectively activate M~1~ receptors through an allosteric mechanism, as shown by mutagenesis and molecular pharmacology studies;^[@ref50]−[@ref52]^ in other reports, **11** was described as a bitopic M~1~R ligand.^[@ref53]^ Likewise, compound **12** (cf. [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B) was suggested to be a bitopic M~1~R ligand.^[@ref54]^ MR antagonists **3** and **4** (cf. [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A) are nonselective orthosteric MR antagonists with high affinities \[*K*~i~ (**3**, M~1~R--M~5~R): 0.52--3.80 nM and *K*~i~ (**4**, M~1~R--M~4~R): 0.057--0.33 nM\].^[@ref45],[@ref55]^ In addition to the heterodimeric ligands, one monomeric and four homodimeric ligands derived from xanomeline, one monomeric and two homodimeric ligands derived from **8**, and a monomeric ligand derived from **11** were prepared as reference compounds. Furthermore, two radiolabeled heterodimeric ligands (types "**8--11**" and "**8--1**") were prepared and characterized by saturation binding \[including experiments in the presence of allosteric modulators (Schild-like analysis)\], kinetic investigations, and competition-binding studies.

2. Results and Discussion {#sec2}
=========================

2.1. Chemistry {#sec2-1}
--------------

Monomeric reference compound **22** and homodimeric xanomeline-derived ligand **25** were prepared by N-alkylation of homopiperazine derivative **21** using bromide **20** \[followed by removal of the *tert*-butoxycarbonyl (Boc) group\] and by alkylation of piperazine (**24**) using bromide **23**, respectively ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). Treatment of amine **26** with octanedioyl dichloride or decanedioyl dichloride in the presence of triethylamine yielded homodimeric xanomeline-type compounds **27** and **28**, respectively. Likewise, amidation of terephthalic acid with amine **26**, using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)/1-hydroxybenzotriazole hydrate (HOBt) as coupling reagent, afforded homodimeric ligand **29** containing a rigid central linker moiety. N-alkylation of **21** using bromide **30**, followed by removal of the Boc group, afforded TBPB derivative **31** ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).

![Synthesis of Xanomeline Derivatives **22**, **25**, and **27--29** as well as TBPB Derivative **31**\
Reagents and conditions: (a) (1) K~2~CO~3~, MeCN, microwave 110 °C, 30 min; (2) trifluoroacetic acid (TFA)/CH~2~Cl~2~ 1:4 v/v, room temperature (rt), 8 h, 66% (**22**), 20% (**31**); (b) K~2~CO~3~, MeCN, microwave 110 °C, 30 min, 22%; (c) octanedioyl dichloride or decanedioyl dichloride, triethylamine, tetrahydrofuran (THF), 0 °C/rt, overnight, 39% (**27**), 65% (**28**); (d) terephthalic acid, EDC, HOBt, dimethylformamide (DMF), rt, overnight, 26%.](ao-2017-01085p_0008){#sch1}

The "**8--11**" type heterodimeric ligand **34** was prepared by N-alkylation of compound **32** using bromide **33**; N-alkylation of **21** using **33**, followed by removal of the Boc group yielded monomeric reference compound **35** ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). Likewise, N-alkylation of piperazine derivatives **36** and **37**, using bromide **33**, gave the "**8--4**" type heterodimeric ligands **38** and **39**. The "**8--1**" type heterodimeric ligand **43** was prepared through N-alkylation of compound **40** by applying a mixture of bromides **20** and **33**, followed by Boc-deprotection ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). Homodimeric ligand **41**,^[@ref23]^ obtained as a "byproduct" (after Boc-deprotection), was isolated as well. Compound **41** was recently used as an amine precursor for the preparation of a tritium-labeled homodimeric MR ligand.^[@ref23]^ Amine **43** was propionylated to give congener **44**. The "**8--1**" type ligand **46** was obtained by N-alkylation of **45** by bromide **33** ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). The "**8--3**" type heterodimeric ligand **48** and the "**8--12**" type ligand **50** were synthesized by alkylation of compound **47** using bromide **33** and by alkylation of amine **9**([@ref22]) (cf. [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A) using bromide **49**, respectively ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). Treatment of **40** with a mixture of bromides **30** and **33**, followed by Boc-deprotection, gave the "**8--11**" type heterodimeric ligand **51**, which contains a rigid homopiperazine moiety in between the pharmacophores. As in the case of the synthesis of **43**, homodimeric "byproduct" **41** was isolated. Propionylation of **51** gave congener **52** ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). Homodimeric ligand **54** was obtained by treating an excess of compound **47** with bromide **53** ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). Regarding the syntheses of **43** and **51**, it should be mentioned that the respective non-DIBA type homodimeric ligands, resulting from a double alkylation of **40** with bromides **20** or **30**, were formed as well, but were not isolated because of interference with other impurities \[preparative high-performance liquid chromatography (HPLC)\].

![Synthesis of DIBA (**8**)-Derived Heterodimeric Ligands **34**, **38**, **39**, **43**, **44**, **46**, **48**, and **50--52**, Monomeric Dibenzodiazepinone Derivative **35**, and 4-DAMP (**3**)-Derived Homodimeric Ligand **54**\
Reagents and conditions: (a) K~2~CO~3~, MeCN, reflux, 3--6 h, 57% (**34**), 51% (**38**), 38% (**39**), 41% (**46**), 27% (**48**); (b) (1) K~2~CO~3~, MeCN, reflux (3 h or overnight) or microwave 110 °C (30 min); (2) TFA/CH~2~Cl~2~/H~2~O 10:10:1 v/v/v, rt, 2 h, 12% (**35**), 17% (**43**), 12% (**51**); (c) diisopropylethylamine (DIPEA), DMF, rt, 2 h, 95% (**44**), 96% (**52**); (d) NaI, K~2~CO~3~, MeCN, reflux, 3 h, 52%; (e) K~2~CO~3~, MeCN, microwave 110 °C, 45 min, 23%.](ao-2017-01085p_0009){#sch2}

Amidation of isophthalic acid derivative **57** by applying a mixture of amines **55** and **56**, followed by Boc-deprotection, afforded heterodimeric ligand **60** and homodimeric ligand **58** ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}). Propionylation of **58** and **60** gave congeners **59** and **61**, respectively. By analogy, heterodimeric ligands **63**, **66**, **69**, and **72** were obtained by amidation of **57** using the amine mixtures **55**/**62**, **55**/**65**, **55**/**68**, and **55**/**71**, respectively, and subsequent Boc-deprotection ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}). Propionylation of **63**, **66**, and **69** at the central linker moiety afforded propionamide congeners **64**, **67**, and **70**. It should be noted that the respective non-DIBA type homodimeric ligands, generated by double amidation of **57** with amines **56**, **62**, **65**, **68**, or **71**, were formed but were not isolated (cf. [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}).

![Synthesis of Dibenzodiazepinone-Type Homo- or Heterodimeric Ligands **58--61**, **63**, **64**, **66**, **67**, **69**, **70**, and **72**\
Reagents and conditions: (a) (1) 2-(1*H*-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium, HOBt, DIPEA, DMF, 60 °C, 3 h; (2) TFA/CH~2~Cl~2~/H~2~O 10:10:1 v/v/v, rt, 2 h, 8% (**58**), 16% (**60**), 10% (**63**), 28% (**66**), 15% (**69**), 4% (**72**); (b) DIPEA, DMF, rt, 2 h, 79% (**59**), 89% (**61**), 88% (**64**), 83% (**67**), 86% (**70**).](ao-2017-01085p_0010){#sch3}

2.2. Competition Binding at the Human MR Subtypes M~1--5~ with \[^3^H\]N-Methylscopolamine (\[^3^H\]**5**) as the Radioligand {#sec2-2}
-----------------------------------------------------------------------------------------------------------------------------

### 2.2.1. M~2~R Affinity {#sec2-2-1}

M~2~R receptor-binding affinities of monomeric reference ligands **22**, **31**, and **35**, homodimeric ligands **54** (type "**3--3**"), **58**, **59** (type "**8--8**"), and **25**, **27--29** (type "**1--1**"), as well as heterodimeric ligands **43**, **44**, **46**, **60**, and **61** (type "**8--1**"), **34**, **51**, **52**, **63**, and **64** (type "**8--11**"), **50** and **72** (type "**8--12**"), **38**, **39**, **69**, and **70** (type "**8--4**"), and **48**, **66**, and **67** (type "**8--3**") were determined at live CHO-hM~2~R cells in equilibrium-binding experiments using the MR antagonist \[^3^H\]**5** as the orthosterically binding radioligand. The results are summarized in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}.

###### MR Affinities (p*K*~i~ Values) of Monomeric Reference Compounds **22**, **31**, and **35**, Homodimeric Ligands **25**, **27--29**, **54**, **58**, and **59**, as well as Heterodimeric Ligands **34**, **38**, **39**, **43**, **44**, **46**, **48**, **50--52**, **60**, **61**, **63**, **64**, **66**, **67**, **69**, **70**, and **72** Obtained from Equilibrium Competition-Binding Studies with \[^3^H\]**5** at Live CHO-hM~*x*~R Cells (*x* = 1--5)

           M~1~R         M~2~R                                           M~3~R          M~4~R                                           M~5~R                                                                                                                                     
  -------- ------------- ----------------------------------------------- -------------- ----------------------------------------------- ------------- ----------------------------------------------- ------------- ----------------------------------------------- ------------- ---------------
  **22**   n.d.          n.d.                                            4.90 ± 0.16    --1.01 ± 0.10                                   n.d.          n.d.                                            n.d.          n.d.                                            n.d.          n.d
  **25**   7.36 ± 0.10   --1.04 ± 0.07                                   7.75 ± 0.18    --0.92 ± 0.18                                   7.30 ± 0.02   --0.95 ± 0.04                                   n.d.          n.d.                                            n.d.          n.d.
  **27**   8.30 ± 0.08   --0.89 ± 0.10                                   8.46 ± 0.17    --0.94 ± 0.08                                   8.14 ± 0.04   --1.14 ± 0.03                                   n.d.          n.d.                                            n.d.          n.d.
  **28**   8.41 ± 0.05   --1.30 ± 0.05                                   8.67 ± 0.11    --0.84 ± 0.07                                   n.d.          n.d.                                            n.d.          n.d.                                            n.d.          n.d.
  **29**   7.72 ± 0.13   --1.15 ± 0.18                                   8.38 ± 0.13    --0.83 ± 0.06                                   n.d.          n.d.                                            n.d.          n.d.                                            n.d.          n.d.
  **31**   n.d.          n.d.                                            5.88 ± 0.29    --0.87 ± 0.05                                   n.d.          n.d.                                            n.d.          n.d.                                            n.d.          n.d.
  **34**   8.57 ± 0.05   --1.13 ± 0.05                                   9.12 ± 0.05    --1.43 ± 0.20                                   7.01 ± 0.11   --1.12 ± 0.07                                   7.95 ± 0.50   --1.18 ± 0.06                                   7.09 ± 0.07   --1.09 ± 0.20
  **35**   7.26 ± 0.10   0.92 ± 0.08                                     8.67 ± 0.03    --0.87 ± 0.09                                   6.25 ± 0.06   --0.93 ± 0.20                                   8.00 ± 0.01   --0.77 ± 0.02[b](#t1fn2){ref-type="table-fn"}   6.86 ± 0.17   --1.09 ± 0.15
  **38**   8.47 ± 0.08   --1.03 ± 0.12                                   8.82 ± 0.14    --1.08 ± 0.22                                   8.12 ± 0.05   --1.36 ± 0.09                                   7.99 ± 0.28   --0.98 ± 0.12                                   8.47 ± 0.06   --1.17 ± 0.10
  **39**   7.62 ± 0.19   --1.40 ± 0.30                                   8.37 ± 0.28    --1.51 ± 0.26                                   7.01 ± 0.10   --0.85 ± 0.04                                   7.52 ± 0.35   --1.25 ± 0.10                                   7.03 ± 0.03   --1.09 ± 0.18
  **43**   8.35 ± 0.07   --1.47 ± 0.17                                   9.30 ± 0.05    --2.19 ± 0.06[b](#t1fn2){ref-type="table-fn"}   7.21 ± 0.04   --1.34 ± 0.16                                   n.d.          n.d.                                            n.d.          n.d.
  **44**   8.39 ± 0.03   --1.05 ± 0.05                                   9.34 ± 0.03    --1.14 ± 0.07                                   6.84 ± 0.03   --0.93 ± 0.04                                   8.24 ± 0.08   --0.94 ± 0.06                                   7.00 ± 0.09   --1.21 ± 0.19
  **46**   8.84 ± 0.11   --1.45 ± 0.02[b](#t1fn2){ref-type="table-fn"}   10.14 ± 0.11   --0.96 ± 0.05                                   7.88 ± 0.06   --1.17 ± 0.08                                   8.59 ± 0.05   --1.17 ± 0.04                                   7.47 ± 0.03   --1.07 ± 0.22
  **48**   7.68 ± 0.12   --1.03 ± 0.22                                   8.66 ± 0.03    --1.24 ± 0.22                                   7.46 ± 0.12   --1.35 ± 0.06[b](#t1fn2){ref-type="table-fn"}   8.07 ± 0.19   --1.17 ± 0.11                                   7.27 ± 0.05   --1.11 ± 0.10
  **50**   8.40 ± 0.08   --1.00 ± 0.05                                   9.24 ± 0.11    --1.38 ± 0.22                                   6.86 ± 0.04   --1.05 ± 0.09                                   8.48 ± 0.03   --1.4 ± 0.06                                    7.03 ± 0.07   --1.01 ± 0.25
  **51**   8.37 ± 0.03   --1.47 ± 0.05[b](#t1fn2){ref-type="table-fn"}   9.16 ± 0.07    --1.86 ± 0.05[b](#t1fn2){ref-type="table-fn"}   7.23 ± 0.06   --1.05 ± 0.10                                   n.d.          n.d.                                            n.d.          n.d.
  **52**   7.78 ± 0.08   --1.82 ± 0.19[b](#t1fn2){ref-type="table-fn"}   9.11 ± 0.10    --1.12 ± 0.15                                   6.23 ± 0.10   --1.01 ± 0.03                                   8.10 ± 0.11   --0.85 ± 0.07                                   6.88 ± 0.10   --1.31 ± 0.10
  **54**   6.59 ± 0.07   --1.14 ± 0.12                                   6.05 ± 0.06    --1.33 ± 0.18                                   5.64 ± 0.09   --1.05 ± 0.34                                   5.63 ± 0.04   --1.00 ± 0.06                                   5.87 ± 0.25   --1.35 ± 0.20
  **58**   8.69 ± 0.09   --2.06 ± 0.19[b](#t1fn2){ref-type="table-fn"}   9.83 ± 0.07    --1.53 ± 0.15                                   7.78 ± 0.05   --1.27 ± 0.10                                   n.d.          n.d.                                            n.d.          n.d.
  **59**   8.53 ± 0.08   --1.75 ± 0.34                                   9.24 ± 0.06    --1.31 ± 0.09                                   7.89 ± 0.07   --1.22 ± 0.09                                   n.d.          n.d.                                            n.d.          n.d.
  **60**   8.80 ± 0.10   --1.32 ± 0.31                                   9.65 ± 0.15    --1.79 ± 0.09[b](#t1fn2){ref-type="table-fn"}   7.76 ± 0.14   --1.28 ± 0.04[b](#t1fn2){ref-type="table-fn"}   n.d.          n.d.                                            n.d.          n.d.
  **61**   8.88 ± 0.08   --1.61 ± 0.03[b](#t1fn2){ref-type="table-fn"}   9.47 ± 0.07    --2.37 ± 0.15[b](#t1fn2){ref-type="table-fn"}   7.87 ± 0.02   --0.99 ± 0.04                                   8.87 ± 0.08   --1.14 ± 0.11                                   8.37 ± 0.24   --1.02 ± 0.11
  **63**   8.79 ± 0.09   --1.19 ± 0.07                                   9.71 ± 0.08    --1.37 ± 0.14                                   7.77 ± 0.03   --1.22 ± 0.05                                   n.d.          n.d.                                            n.d.          n.d.
  **64**   8.56 ± 0.11   --1.59 ± 0.15                                   9.44 ± 0.06    --1.84 ± 0.17[b](#t1fn2){ref-type="table-fn"}   7.55 ± 0.04   --1.40 ± 0.10                                   8.57 ± 0.02   --1.01 ± 0.04                                   6.96 ± 0.04   --1.26 ± 0.14
  **66**   8.28 ± 0.05   --1.32 ± 0.19                                   9.16 ± 0.20    --1.64 ± 0.23                                   7.20 ± 0.19   --1.33 ± 0.08                                   n.d.          n.d.                                            n.d.          n.d.
  **67**   8.38 ± 0.06   --1.54 ± 0.14                                   8.94 ± 0.07    --2.14 ± 0.16[b](#t1fn2){ref-type="table-fn"}   7.52 ± 0.04   --1.25 ± 0.09                                   8.50 ± 0.08   --1.52 ± 0.26                                   7.62 ± 0.06   --1.51 ± 0.12
  **69**   8.42 ± 0.19   --1.74 ± 0.19                                   9.17 ± 0.18    --1.52 ± 0.31                                   7.26 ± 0.22   --1.23 ± 0.12                                   n.d.          n.d.                                            n.d.          n.d.
  **70**   8.51 ± 0.13   --1.10 ± 0.07                                   8.96 ± 0.08    --2.14 ± 0.18[b](#t1fn2){ref-type="table-fn"}   7.72 ± 0.06   --1.21 ± 0.13                                   8.29 ± 0.02   --1.41 ± 0.05[b](#t1fn2){ref-type="table-fn"}   7.37 ± 0.08   --1.01 ± 0.12
  **72**   8.52 ± 0.09   --1.66 ± 0.20                                   9.63 ± 0.03    --1.31 ± 0.13                                   7.88 ± 0.03   --1.42 ± 0.09[b](#t1fn2){ref-type="table-fn"}   8.39 ± 0.09   --1.50 ± 0.17                                   7.69 ± 0.33   --0.85 ± 0.07

Curve slope of the four-parameter logistic fit. Presented are mean values ± SEM from three to five independent experiments (each performed in triplicate). *K*~d~ values reported previously^[@ref22]^/applied concentrations of \[^3^H\]**5**: M~1~: 0.12/0.2 nM; M~2~: 0.090/0.2 nM; M~3~: 0.0895/0.2 nM; M~4~: 0.040/0.1 nM; and M~5~: 0.24/0.3 nM.

Slope different from unity (*P* \< 0.05).

All compounds containing a dibenzodiazepinone moiety showed high M~2~R affinity (p*K*~i~ \> 8.3). Whereas homodimeric derivatives (**25**, **27--29**) of MR agonist **1** exhibited an increased M~2~R affinity (p*K*~i~ \> 7.7) compared to the parent compound (p*K*~i~ of **1**: 6.55, see [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}); the opposite was found in the case of MR antagonist **3** \[p*K*~i~ = 7.09 ± 0.04, mean ± standard error of the mean (SEM) from two independent experiments\] and a homodimeric derivative of **3** (compound **54**, p*K*~i~ = 6.05, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). The "**8--1**" type heterodimeric ligand **46** displayed the highest M~2~R affinity (p*K*~i~ = 10.14, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Steep curve slopes (≤−1.79) were observed for **43**, **51**, **60**, **61**, **64**, **67**, and **70**, indicating a complex mechanism of binding (e.g., the involvement of more than one binding site).

### 2.2.2. MR Receptor Subtype Selectivity {#sec2-2-2}

Selected dibenzodiazepinone-type heterodimeric ligands (**34**, **38**, **39**, **44**, **46**, **48**, **50**, **52**, **61**, **64**, **67**, **70**, and **72**) and monomeric dibenzodiazepinone derivative **35**, containing an amino-functionalized homopiperazine moiety, were also investigated by equilibrium competition binding at the MR subtypes M~1~, M~3~, M~4~, and M~5~ with \[^3^H\]**5** as the radioligand ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). For all compounds, there was a preference for the M~2~R. Except for **38**, the M~1~R and M~4~R affinities were higher than the M~3~R and M~5~R affinities, that is, the selectivity profile was M~2~ \> M~1~ ≈ M~4~ \> M~3~/M~5~ (**34**, **39**, **44**, **46**, **48**, **50**, **52**, **61**, **64**, **67**, **70**, and **72**) and M~2~ \> M~1~ ≈ M~5~ \> M~3~ \> M~4~ in the case of **38** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Compound **46**, showing the highest M~2~R affinity among the studied MR ligands, exhibited a more pronounced M~2~R selectivity than the pyridobenzodiazepinone-type ligand **7** (cf. [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A),^[@ref45]^ the MR antagonist tripitramine^[@ref56]^ containing three pyridobenzodiazepinone moieties, as well as the recently reported dibenzodiazepinone derivatives **10** and **19** (cf. [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}C).^[@ref23]^ Displacement of \[^3^H\]**5** by **46** as well as by heterodimeric ligands **44** and **64**, which were prepared as tritiated ligands (see below), from M~*x*~Rs (determined at CHO-hM~*x*~R cells, *x* = 1--5) is illustrated in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}.

![Displacement of \[^3^H\]**5** \[*c* = 0.2 nM (M~1~, M~2~, M~3~), 0.1 nM (M~4~), or 0.3 nM (M~5~)\] by heterodimeric ligands **44** (A), **46** (B), and **64** (C) from M~*x*~Rs determined at intact CHO-hM~*x*~R cells (*x* = 1--5). Data represent mean values ± SEM from at least three independent experiments (performed in triplicate).](ao-2017-01085p_0002){#fig2}

2.3. Effect on IP1 Accumulation {#sec2-3}
-------------------------------

As previously reported for homodimeric dibenzodiazepinone derivative **19**,^[@ref23]^ the homodimeric xanomeline-type ligand **25** and the heterodimeric dibenzodiazepinone-type ligands **44**, **46**, and **64** were investigated with respect to M~2~R agonism and antagonism in an IP accumulation assay ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). Like **19**, compounds **44**, **46**, and **64** did not induce an IP1 accumulation when investigated in the agonist mode ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A), but completely suppressed the effect of CCh when studied in the antagonist mode ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B), revealing that the combination of the agonist xanomeline (**1**) with a dibenzodiazepinone-type antagonist in one molecule (e.g., **44**) resulted in a loss of agonistic activity. Interestingly, homodimeric ligand **25**, which is derived from MR agonist **1**, proved to be a M~2~R antagonist in contrast to parent compound **1** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). The p*K*~b~ values of **44**, **46**, and **64** (cf. [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B) were lower compared to the respective p*K*~i~ values (cf. [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}), as previously observed for homodimeric ligand **19**.^[@ref23]^ Possible reasons for this discrepancy are discussed elsewhere.^[@ref23]^

![M~2~R agonism and antagonism of **25**, **44**, **46**, and **64** investigated in an IP1 accumulation assay using HEK-hM~2~-Gαq~i5-HA~ cells. (A) Concentration-dependent effect of CCh, **1**, **25**, **44**, **46**, and **64** on the accumulation of IP1. **25**, **44**, **46**, and **64** elicited no response. pEC~50~ of CCh and **1**:6.96 and 7.45, respectively. Data represent mean values ± SEM from at least seven (CCh and **1**) or at least two (**25**, **44**, **46**, and **64**) independent experiments (each performed in triplicate). (B) Concentration-dependent inhibition of the IP1 accumulation induced by CCh (0.3 μM) by **6**, **25**, **44**, **46**, and **64**. Corresponding p*K*~b~ values: **6**: 8.63,^[@ref23]^**25**: 7.21, **44**: 7.18, **46**: 7.67, and **64**: 7.93. Data represent mean values ± SEM from at least five independent experiments (each performed in duplicate).](ao-2017-01085p_0003){#fig3}

2.4. Synthesis of the Radiolabeled Ligands \[^3^H\]**44** and \[^3^H\]**64** {#sec2-4}
----------------------------------------------------------------------------

Aiming at a radiolabeled derivative of heterodimeric ligand **46**, which exhibited the highest M~2~R affinity and selectivity (cf. [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}), compound **44**, containing a propionamido-substituted homopiperazine moiety instead of the piperazine ring in **46** (cf. [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}), was prepared as a tritiated derivative from amine precursor **43** and commercially available \[^3^H\]**42** ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A). Additionally, the tritiated derivative of heterodimeric ligand **64** was prepared from **63** and \[^3^H\]**42** ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A). The chemical stabilities of the "cold" analogues **44** and **64** were investigated under assaylike conditions \[phosphate-buffered saline (PBS) pH 7.4\] for over 48 h. **44** and **64** proved to be stable under these conditions (cf. SI Figure 1, [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01085/suppl_file/ao7b01085_si_001.pdf)). \[^3^H\]**44** and \[^3^H\]**64** were obtained in high radiochemical purities (98% and 99%, respectively; [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B,D) and showed a high (\[^3^H\]**44**) and excellent (\[^3^H\]**64**) stability when stored in ethanol at −20 °C (cf. [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}C,E).

![Preparation, purity, and identity control of the radiolabeled dibenzodiazepinone derivatives \[^3^H\]**44** and \[^3^H\]**64**. (A) Synthesis of \[^3^H\]**44** and \[^3^H\]**64** by \[^3^H\]propionylation of amine precursors **43** and **63**, respectively, using succinimidyl \[^3^H\]propionate (\[^3^H\]**42**). Reagents and conditions: (a) DIPEA, DMF, rt, 1.5 h, radiochemical yields: 36% (\[^3^H\]**44**) and 35% (\[^3^H\]**64**). (B,C) HPLC analysis of \[^3^H\]**44** (0.18 μM) spiked with "cold" **44** (3 μM), analyzed 3 days after synthesis (B) and after 10 months of storage at −20 °C in EtOH/H~2~O (1:1) (C). (D,E) HPLC analysis of \[^3^H\]**64** (0.23 μM) spiked with "cold" **64** (3 μM), analyzed 3 days after synthesis (D) and after 10 months of storage at −20 °C in EtOH/H~2~O (1:1) (E). HPLC conditions are provided in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01085/suppl_file/ao7b01085_si_001.pdf).](ao-2017-01085p_0004){#fig4}

2.5. Characterization of \[^3^H\]**44** and \[^3^H\]**64** {#sec2-5}
----------------------------------------------------------

Saturation-binding experiments with \[^3^H\]**44** and \[^3^H\]**64** at intact CHO-hM~2~R cells or CHO-hM~2~R cell homogenates yielded monophasic saturation isotherms ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}). As previously reported for \[^3^H\]**19**,^[@ref23]^ the extent of unspecific binding strongly depended on the assay conditions: in the case of experiments performed at intact adherent cells (white/transparent 96-well plates), unspecific binding was considerably higher compared to experiments performed at cell homogenates, which preclude the unspecific binding of the radioligand to the microplate ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}).^[@ref23]^ The apparent *K*~d~ values amounted to 1.0 and 0.081 nM (cell homogenates, [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). As orthosteric antagonist **6** (used to determine unspecific binding) completely prevented hyperbolic (monophasic) binding of the radioligands to the M~2~R, these experiments proved that \[^3^H\]**44** and \[^3^H\]**64** bind to the orthosteric binding site of the M~2~R, as previously reported for \[^3^H\]**19**.^[@ref23]^

![Representative hyperbolic (monophasic) isotherms of specific M~2~R binding (red dashed line) of \[^3^H\]**44** (A,B) and \[^3^H\]**64** (C,D) obtained from saturation-binding experiments either performed with live adherent CHO-hM~2~R cells (A,C) or CHO-hM~2~R cell homogenates (B,D). Unspecific binding (blue solid line) was determined in the presence of MR antagonist **6** (500-fold excess). Experiments were performed in triplicate. The error bars of specific binding and error bars in the Scatchard plots represent propagated errors calculated according to the Gaussian law of errors. The error bars of total and unspecific binding represent the SEM.](ao-2017-01085p_0005){#fig5}

###### M~2~R Binding Characteristics of \[^3^H\]**44** and \[^3^H\]**64**

                   saturation-binding   binding kinetics                   
  ---------------- -------------------- ------------------ --------------- -----------------------
  \[^3^H\]**44**   1.0 ± 0.2            0.20 ± 0.03        0.078 ± 0.015   0.015 ± 0.001, 47 ± 3
  \[^3^H\]**64**   0.081 ± 0.022        0.072 ± 0.002      0.31 ± 0.01     0.022 ± 0.002, 35 ± 1

Dissociation constant determined by saturation binding at CHO-hM~2~R cell homogenates; mean ± SEM from at least three independent experiments (performed in triplicate).

Kinetically derived dissociation constant ± propagated error \[*K*~d~(kin) = *k*~off~/*k*~on~\].

Association rate constant ± propagated error, calculated from *k*~obs~ (nonlinear regression), *k*~off~ (nonlinear regression), and the applied radioligand concentration (cf. [Radioligand Binding](#sec4-6){ref-type="other"}).

Dissociation rate constant (nonlinear regression, two (\[^3^H\]**44**)- or three (\[^3^H\]**64**)-parameter equation describing a monophasic decline) and half-life; mean ± SEM from three independent experiments (performed in triplicate).

The association of \[^3^H\]**44** and \[^3^H\]**64** with the human M~2~R was monophasic and yielded similar *k*~on~ values ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}A,C, [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). Whereas the "**8--1**" type heterodimeric ligand \[^3^H\]**44** dissociated completely from the M~2~R (*t*~1/2~ = 47 min, cf. [Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}B, [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}), the dissociation of the "**8--11**" type dimeric ligand \[^3^H\]**64** was incomplete, reaching a plateau at approximately 47% of initially M~2~R-bound \[^3^H\]**64** (*t*~1/2~ = 35 min, cf. [Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}D, [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). An incomplete ligand dissociation, which might be attributed to conformational adjustments of the receptor upon ligand binding^[@ref57]^ or an enhanced rebinding capability of the dimeric ligand,^[@ref58]^ was also reported for the homodimeric dibenzodiazepinone-type ligand \[^3^H\]**19**.^[@ref23]^ The kinetically derived dissociation constants of both \[^3^H\]**44** and \[^3^H\]**64** \[*K*~d~(kin): 0.33 and 0.057 nM, respectively\] were in good accordance with the *K*~d~ values obtained from the saturation-binding experiments ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}).

![Association and dissociation kinetics of \[^3^H\]**44** (A,B) and \[^3^H\]**64** (C,D) determined at CHO-hM~2~R cell homogenates at 23 °C. (A) Association of \[^3^H\]**44** (*c* = 2 nM) with the M~2~R. Inset: ln\[*B*~(eq)~/(*B*~(eq)~ -- *B*~(*t*)~)\] vs time. (B) Dissociation of \[^3^H\]**44** (preincubation: 4 nM, 1 h) from the M~2~R determined in the presence of **6** (1000-fold excess), showing complete monophasic exponential decline. Inset: ln\[*B*~(*t*)~/*B*~(0)~\] vs time. (C) Association of \[^3^H\]**64** (*c* = 0.6 nM) with the M~2~R. Inset: ln\[*B*~(eq)~/(*B*~(eq)~ -- *B*~(*t*)~)\] vs time. (D) Dissociation of \[^3^H\]**64** (preincubation: 0.6 nM, 1 h) from the M~2~R determined in the presence of **6** (1000-fold excess), showing incomplete monophasic exponential decline. Inset: ln\[(*B*~(*t*)~ -- *B*~(plateau)~/*B*~(0)~\] versus time. For *k*~on~ and *k*~off~ values, see [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}. Data represent mean ± SEM from three (A,B,D) or two (C) independent experiments (each performed in triplicate).](ao-2017-01085p_0006){#fig6}

2.6. Competition Binding at the M~2~R Using \[^3^H\]**44** and \[^3^H\]**64** as Radioligands {#sec2-6}
---------------------------------------------------------------------------------------------

Heterodimeric radioligands \[^3^H\]**44** and \[^3^H\]**64** were applied to equilibrium competition-binding experiments at CHO-hM~2~R cell homogenates involving various reported orthosteric, dualsteric, and allosteric MR ligands. Orthosteric MR antagonist **6**, dualsteric ligand **10**, and allosteric modulator **14** (cf. [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) were capable of totally displacing \[^3^H\]**44** from the M~2~R (SI Figure 2A, [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01085/suppl_file/ao7b01085_si_001.pdf)), indicating either a competitive mechanism or a strongly negative cooperativity between dimeric ligand \[^3^H\]**44** and **6**, **10**, or **14**. Likewise, orthosteric ligands **1** and **6**, dualsteric ligands **7** and **10**, as well as allosteric modulators **13--15** (cf. [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) completely displaced \[^3^H\]**64** from the M~2~R-specific binding sites. (SI Figure 2B, [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01085/suppl_file/ao7b01085_si_001.pdf)). For most of the investigated MR ligands, the respective p*K*~i~ values were in good agreement with the binding data obtained from competition binding with \[^3^H\]**5** ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}). However, the p*K*~i~ values of compounds **1**, **6**, **7**, and **10**, determined in the presence of \[^3^H\]**64**, were consistently lower (up to 1 log unit in the case of **7**) than p*K*~i~ values from the competition-binding experiments with \[^3^H\]**5**. This is in agreement with the (in part) irreversible M~2~R binding of \[^3^H\]**64** (cf. [Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}D), which compromises its use as a molecular tool for the determination of binding constants of nonlabeled ligands, as was also reported for homodimeric MR ligand \[^3^H\]**19**.^[@ref23]^

###### M~2~R Binding Data (p*K*~i~ or pIC~50~ Values) of Various Orthosteric (**1** and **6**), Allosteric (**13--15**), Dualsteric (**7** and **10**) MR Ligands, and **64** Determined with \[^3^H\]**44**, \[^3^H\]**64**, or \[^3^H\]**5**

  ligand   \[^3^H\]**44** p*K*~i~[a](#t3fn1){ref-type="table-fn"}   \[^3^H\]**64** p*K*~i~[a](#t3fn1){ref-type="table-fn"}   \[^3^H\]**5** p*K*~i~\* or pIC~50~\*\*[b](#t3fn2){ref-type="table-fn"}
  -------- -------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------------------
  **1**                                                             5.78 ± 0.05                                              6.55 ± 0.05\*
  **6**    8.52 ± 0.26                                              8.52 ± 0.14                                              9.04 ± 0.08\*
  **7**                                                             7.71 ± 0.14                                              8.71 ± 0.05\*
  **10**   9.61 ± 0.11                                              8.35 ± 0.09                                              9.11 ± 0.05\*
  **13**                                                            5.60 ± 0.07                                              6.11 ± 0.09\*\*[c](#t3fn3){ref-type="table-fn"}
  **14**   5.90 ± 0.22                                              6.08 ± 0.28                                              6.32 ± 0.18\*\*[c](#t3fn3){ref-type="table-fn"}
  **15**                                                            5.43 ± 0.02                                              \<4.5\*\*[c](#t3fn3){ref-type="table-fn"}
  **64**                                                            9.44 ± 0.01                                              9.44 ± 0.06\*

Determined by equilibrium competition binding with \[^3^H\]**44** (2 nM) or \[^3^H\]**64** (0.3 nM) at CHO-hM~2~R cell homogenates; mean values ± SEM from at least three independent experiments (performed in triplicate).

Determined by equilibrium competition binding with \[^3^H\]**5** (0.2 nM) at live CHO-hM~2~R cells; mean ± SEM from at least three independent experiments (performed in triplicate).

Reported by Pegoli et al.^[@ref23]^

2.7. Schild-like Analysis with \[^3^H\]**64** and Allosteric M~2~R Modulator **14** {#sec2-7}
-----------------------------------------------------------------------------------

To further explore the binding mode of heterodimeric ligand **64** at the M~2~R, saturation-binding experiments were performed with \[^3^H\]**64** in the presence of increasing concentrations of allosteric M~2~R ligand **14** ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}), as recently reported for homodimeric radioligand \[^3^H\]**19**.^[@ref23]^ As in the case of \[^3^H\]**19**,^[@ref23]^ this Schild-like analysis resulted in rightward-shifted saturation isotherms of \[^3^H\]**64** ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}A) and a linear Schild plot with a slope not different from unity ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}B), which is consistent with a competitive mechanism between \[^3^H\]**64** and allosteric M~2~R ligand **14**. With regard to the fact that \[^3^H\]**64** binds to the orthosteric binding site of the M~2~R (see above), these results strongly support a dualsteric binding mode of **64** at the human M~2~R. The "p*A*~2~" value of 7.16, obtained for **14** from the Schild regression ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}B), was in accordance with the reported M~2~R binding data of **14** (p*K*~X~ 7.50^[@ref59]^).

![Effect of allosteric M~2~R modulator **14** on the saturation binding of \[^3^H\]**64** determined at CHO-hM~2~R cell homogenates at 22 °C. (A) Isotherms of specific radioligand binding plotted in the linear and semilogarithmic scale. The presence of compound **14** led to a rightward shift of the saturation isotherms of \[^3^H\]**64**. (B) "Schild" regression resulting from the rightward shifts (Δp*K*~d~) of the saturation isotherms \[log(*r* -- 1) plotted vs log(concentration **14**), where *r* = 10^Δp*K*~d~^\]. The slope of the linear Schild regression was not different from unity \[*P* \> 0.5, based on the slope mean value ± SEM (0.99 ± 0.15) from three sets of independent saturation-binding experiments (performed in triplicate)\], suggesting a competitive interaction between \[^3^H\]**64** and **14**. Data represent mean values ± SEM from three independent experiments (each performed in triplicate).](ao-2017-01085p_0007){#fig7}

3. Conclusions {#sec3}
==============

Linking orthosteric (**1**, **3**, and **4**) and allosteric (**11** and **12**) MR ligands with a M~2~R preferring dibenzodiazepinone-type MR antagonist (**8**) yielded a series of heterodimeric ligands (**34**, **38**, **39**, **43**, **44**, **46**, **48**, **50--52**, **60**, **61**, **63**, **64**, **66**, **67**, **69**, **70**, and **72**). The "**8--1**" type dimeric ligand **46** (UR-SK75), containing a piperazine moiety in the linker, exhibited a higher M~2~R affinity (p*K*~i~ 10.14) and selectivity \[expressed as the ratio of *K*~i~ values (M~1~/M~2~/M~3~/M~4~/M~5~): 23:1:180:29:430\] compared to monomeric (such as **8**([@ref46]) and **10**([@ref22],[@ref23])) and homodimeric (e.g., **18**([@ref22]) and **19**([@ref23])) dibenzodiazepinone-type ligands. High M~2~R affinity of all dibenzodiazepinone-type heterodimeric ligands (p*K*~i~ \> 8.3, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}), as also reported for monomeric dibenzodiazepinone-type ligands,^[@ref22]^ suggested a minor influence of the second pharmacophore on M~2~R binding, indicating that the high M~2~R affinity of these compounds is mediated by the "dibenzodiazepinone" pharmacophore, which binds most likely to the orthosteric binding site of the M~2~R. This is supported by the proposed binding mode of **10** and **19** at the M~2~R,^[@ref23]^ by saturation-binding studies using the radioligands \[^3^H\]**44** (\[^3^H\]UR-SK71) and \[^3^H\]**64** (\[^3^H\]UR-SK59), and by the fact that compounds containing M~1~R/M~4~R selective agonist **1**([@ref49]) as a second pharmacophore (**43**, **44**, **46**, **60**, and **61**) proved to be M~2~R-preferring ligands. Moreover, the prototypical heterodimeric ligands **44** and **46** were shown to be M~2~R antagonists (cf. [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). Concerning the "**8--1**" type heterodimeric ligands, one can speculate about the contribution of the pharmacophore of **1** to M~2~R binding because the homodimeric derivatives of **1** (compounds **25**, **27--29**) exhibited considerably higher M~2~R affinities compared to **1**. This work confirms that dibenzodiazepinone-type MR ligands represent a promising class of compounds for the development of highly selective M~2~R ligands with a high receptor affinity based on the dualsteric ligand approach.

4. Methods {#sec4}
==========

4.1. General Experimental Conditions {#sec4-1}
------------------------------------

Reagents and chemicals for synthesis were purchased from Acros Organics (Geel, Belgium), Iris Biotech (Marktredwitz, Germany), Alfa Aesar (Karlsruhe, Germany), Merck (Darmstadt, Germany), Sigma (Munich, Germany), or TCI Europe (Zwijndrecht, Belgium). Technical grade solvents (acetone, ethyl acetate, light petroleum (40--60 °C), and CH~2~Cl~2~) were distilled before use. Deuterated solvents for nuclear magnetic resonance (NMR) spectroscopy were from Deutero (Kastellaun, Germany). Acetonitrile for HPLC (gradient grade) was obtained from Merck or Sigma. Anhydrous DMF was purchased from Sigma. CCh (Sigma) and compounds **6** (Sigma), **7** (Abcam, Cambridge, UK), **13** (Sigma), **14** (Sigma), and **15** (Absource Diagnostic, Munich, Germany) were purchased from commercial suppliers. The radiolabeled MR antagonist \[^3^H\]**5** (specific activity = 80 Ci/mmol) was purchased from American Radiolabeled Chemicals Inc. (St. Louis, MO) via Hartmann Analytic (Braunschweig, Germany). The syntheses of compounds **40**,^[@ref23]^**42**,^[@ref60]^ and **57**([@ref23]) are described elsewhere. Compounds **1**,^[@ref61]^**120**,^[@ref23]^ and **123**([@ref62]) were prepared according to described procedures.

Millipore water was used throughout for the preparation of buffers and HPLC eluents. If moisture-free conditions were required, reactions were performed in dried glassware under an inert atmosphere (argon). Anhydrous THF was obtained by distillation over sodium, and anhydrous CH~2~Cl~2~ was prepared by distillation over P~2~O~5~ after predrying over CaCl~2~. Reactions were monitored by thin-layer chromatography using aluminum plates coated with silica gel (Merck silica gel 60 F~254~, thickness 0.2 mm). Spots were detected by ultraviolet (UV) light (254 or 366 nm) or by staining using 0.3% solution of ninhydrin in *n*-butanol (amines) or iodine. Column chromatography was performed in glass columns on silica gel (Merck silica gel 60, 63--200 μm). Flash chromatography was performed on an Intelli Flash-310 Flash-Chromatography Workstation (Varian, Darmstadt, Germany). Polypropylene reaction vessels (1.5 or 2 mL) with a screw cap (Süd-Laborbedarf, Gauting, Germany) were used for the synthesis of radioligands (\[^3^H\]**44** and \[^3^H\]**64**) for small-scale reactions, for the investigation of chemical stabilities (**44** and **64**), and for the preparation and storage of stock solutions. Melting points were measured with a Büchi 530 (Büchi, Essen, Germany) apparatus and are uncorrected. Microwave-assisted reactions were performed with an Initiator 2.0 synthesizer (Biotage, Uppsala, Sweden). NMR spectra were recorded on a Bruker AVANCE 300 (7.05 T), Bruker AVANCE III HD 400 (9.40 T), or a Bruker AVANCE III HD 600 spectrometer equipped with a cryogenic probe (14.1 T) (Bruker, Karlsruhe, Germany). Abbreviations for the multiplicities of the signals are s (singlet), d (doublet), t (triplet), dd (doublet-of-doublet), q (quartet), m (multiplet), and brs (broad-singlet). Infrared (IR) spectra were measured with a Nicolet 380 FT-IR spectrophotometer (Thermo Electron Corporation). Low-resolution mass spectrometry was performed on a Finnigan SSQ 710A instrument \[chemical ionization mass spectrometry (CI-MS, Thermo Finnigan, San Jose, CA). High-resolution mass spectrometry (HRMS) analysis was performed on an Agilent 6540 UHD Accurate-Mass Q-TOF LC/MS system (Agilent Technologies, Santa Clara, CA) using an electrospray ionization source. Preparative HPLC was performed on a system from Knauer (Berlin, Germany) consisting of two K-1800 pumps and a K-2001 detector. Except for compound **54**, a Kinetex-XB C18 column, 5 μm, 250 × 21 mm (Phenomenex, Aschaffenburg, Germany) served as the stationary phase at a flow rate of 15 mL/min. For the purification of **54**, a Nucleodur 100-5 C18 column, 5 μm, 250 × 21 mm (Macherey-Nagel, Düren, Germany) was used as the stationary phase at a flow rate of 15 mL/min. Mixtures of acetonitrile and 0.1% aq TFA were used as the mobile phase, and a detection wavelength of 220 nm was used throughout. Lyophilization of the collected fractions was performed with an Alpha 2-4 LD apparatus (Martin Christ, Osterode am Harz, Germany). Except for compound **54**, analytical HPLC analysis (purity control) was performed on a system from Merck-Hitachi (Hitachi, Düsseldorf, Germany) composed of a L-6200-A pump, an AS-2000A autosampler, a L-4000A UV detector, and a D-6000 interface. A Kinetex-XB C18 column, 5 μm, 250 mm × 4.6 mm (Phenomenex, Aschaffenburg, Germany) was used as the stationary phase at a flow rate of 0.8 mL/min. Mixtures of acetonitrile (A) and 0.1% aq TFA (B) were used as the mobile phase (degassed by helium purging). The following linear gradient was applied: 0--30 min: A/B 5:95--85:15, 30--32 min: 85:15--95:5, and 32--40 min: 95:5. Detection was performed at 220 nm throughout. The oven temperature was 30 °C. Analytical HPLC analysis of **54** was performed on a system from Thermo Separation Products composed of a SN400 controller, a P4000 pump, a degasser (Degassex DG-4400, Phenomenex), an AS3000 autosampler, and a Spectra Focus ultraviolet--visible detector. A Eurospher-100 C18 column, 5 μm, 250 × 4 mm (Knauer, Berlin, Germany) served as reversed-phase (RP) column at a flow rate of 0.8 mL/min. Mixtures of acetonitrile (A) and 0.05% aq TFA (B) were used as the mobile phase (degassed by helium purging). The oven temperature was set to 30 °C, and detection was performed at 220 nm. The following linear gradient was applied: 0--30 min: A/B 20:80--95:5 and 30--40 min: 95:5.

Annotation concerning the NMR spectra (^1^H, ^13^C) of the dibenzodiazepinone derivatives (**34**, **35**, **38**, **39**, **43**, **44**, **46**, **48**, **50**, **52**, **58--61**, **63**, **64**, **66**, **69**, and **72**): due to a slow rotation about the exocyclic amide group on the NMR time scale, two isomers (ratios provided in the experimental protocols) were evident in the ^1^H- and ^13^C-NMR spectra.

4.2. Compound Characterization {#sec4-2}
------------------------------

Nondescribed intermediate compounds were characterized by ^1^H- and ^13^C-NMR spectroscopy, HRMS, and melting point (if applicable). Target compounds were characterized by ^1^H- and ^13^C-NMR spectroscopy, HRMS, and RP-HPLC analysis. In addition, compounds **44** and **64** were analyzed by IR spectroscopy. Purities determined by analytical RP-HPLC amounted to \>95%.

4.3. Investigation of the Chemical Stability {#sec4-3}
--------------------------------------------

The chemical stability of **44** and **64** was investigated in PBS (pH 7.4) at 22 ± 1 °C. The incubation was started by addition of 10 mM solution of the compounds in dimethylsulfoxide (1 μL) to PBS (99 μL) to give a final concentration of 100 μM. After 0, 12, and 48 h, an aliquot (20 μL) of the solution was taken and added to acetonitrile/0.04% aq TFA (1:9 v/v) (20 μL). An aliquot (20 μL) of the resulting solution was analyzed by RP-HPLC using a system from Agilent Technologies (composed of a 1290 Infinity binary pump equipped with a degasser, a 1290 Infinity autosampler, a 1290 Infinity thermostated column compartment, a 1260 Infinity diode array detector, and a 1260 Infinity fluorescence detector). A Kinetex-XB C18 column, 2.6 μm, 100 × 3 mm (Phenomenex) served as the stationary phase at a flow rate of 0.5 mL/min. The following linear gradient was applied: 0--20 min: acetonitrile/0.04% aq TFA 10:90--68:32, 20--22 min: 68:32--95:5, and 22--28 min: 95:5. The detection wavelength was set to 220 nm.

4.4. Cell Culture and Preparation of Cell Homogenates {#sec4-4}
-----------------------------------------------------

The culture conditions of CHO-K9 cells, stably transfected with the human muscarinic receptors M~1~--M~5~ (obtained from Missouri S&T cDNA Resource Center; Rolla, MO), and the preparation of CHO-hM~2~R cell homogenates are described elsewhere.^[@ref23]^

4.5. IP1 Accumulation Assay {#sec4-5}
---------------------------

The IP1 accumulation assay was performed as described elsewhere.^[@ref23]^

4.6. Radioligand Binding {#sec4-6}
------------------------

Equilibrium competition-binding experiments with \[^3^H\]**5** were performed at intact CHO-hM~*x*~R cells (*x* = 1--5) as described previously,^[@ref22]^ but the total volume per well was 200 μL, that is, in the case of total binding, the wells were filled with 180 μL of L15 medium followed by addition of L15 medium (20 μL) containing \[^3^H\]**5** (10-fold concentrated). To determine the unspecific binding and the effect of a compound of interest on the equilibrium binding \[^3^H\]**5**, the wells were filled with 160 μL of L15 medium followed by addition of L15 medium (20 μL) containing **6** or the compound of interest (10-fold concentrated) and L15 medium (20 μL) containing \[^3^H\]**5** (10-fold concentrated).

Saturation binding with \[^3^H\]**44** and \[^3^H\]**64** at intact CHO-hM~2~R cells was performed in the same manner as saturation-binding experiments with \[^3^H\]**5**^[@ref22]^ with minor modifications: unspecific binding was determined in the presence of **6** (500-fold excess to \[^3^H\]**44** or \[^3^H\]**64**), and the incubation period was 2 h.

Saturation and equilibrium competition-binding experiments with \[^3^H\]**44** and \[^3^H\]**64** at CHO-hM~2~R cell homogenates were performed according to the procedure described for saturation and competition-binding experiments with \[^3^H\]**19** at CHO-hM~2~R cell homogenates,^[@ref23]^ using a total volume per well of 200 instead of 100 μL. The total amount of soluble protein per well was between 19 and 43 μg. In the case of competition-binding experiments, the radioligand concentration was 2.0 and 0.3 nM, respectively. To keep the total volume per well at 200 μL in the case of saturation-binding experiments performed with \[^3^H\]**64** in the presence of **14**, the addition of L15 medium (20 μL) containing **14** (10-fold concentrated) was compensated by an equivalent reduction in the volume of L15 medium added to the wells.

M~2~R association experiments with \[^3^H\]**44** and \[^3^H\]**64** were performed at CHO-hM~2~R cell homogenates essentially using the procedure described for saturation-binding experiments with \[^3^H\]**19** at CHO-hM~2~R cell homogenates.^[@ref23]^ The radioligand concentration was 2 and 0.6 nM, respectively. The incubation was started in reversed order after different periods of time (120--1 min). After last addition of the radioligand, homogenates were collected on filter mats using the Harvester. Unspecific binding was determined in the presence of **6** (500-fold excess to the radioligand). For M~2~R dissociation experiments with \[^3^H\]**44** and \[^3^H\]**64**, performed at CHO-hM~2~R cell homogenates, the procedure was essentially the same as for saturation-binding experiments with \[^3^H\]**19** at CHO-hM~2~R cell homogenates.^[@ref23]^ The preincubation (60 min) of the cell homogenates with the radioligand (\[^3^H\]**44**: 4 nM, \[^3^H\]**64**: 0.6 nM) was started in reversed order after different periods of time (\[^3^H\]**44**: between 180 and 1 min and \[^3^H\]**64**: between 150 and 1 min) by addition of L15 medium (10 μL) containing the radioligand (10-fold concentrated) to the wells preloaded with L15 medium (80 μL) and cell homogenates (10 μL). The dissociation was started by addition of 10 μL of L15 medium containing **6** (40 and 6 μM, respectively) and was stopped by collection and washing of the homogenates using the harvester. To determine unspecific binding, **6** (1000-fold excess to the radioligand) was added during the preincubation step.

4.7. Data Processing {#sec4-7}
--------------------

Retention (capacity) factors were calculated from retention times (*t*~R~) according to *k* = (*t*~R~ -- *t*~0~)/*t*~0~ (*t*~0~ = dead time). Data from the IP1 accumulation assay and radioligand-binding assays \[saturation binding (including Schild-like analysis), association and dissociation kinetics, and equilibrium competition binding\] were processed as described previously.^[@ref23]^ Statistical significance (curve slopes) was assessed by a *t*-test (one-sample, two-tailed). Propagated errors were calculated according to the Gaussian law of errors.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.7b01085](http://pubs.acs.org/doi/abs/10.1021/acsomega.7b01085).Description of the synthesis of intermediates **20**, **21**, **23**, **26**, **30**, **32**, **33**, **36**, **37**, **40**, **42**, **45**, **47**, **49**, **53**, **55--57**, **62**, **65**, **68**, and **71**; experimental protocols for the synthesis and analytical data of compounds **20--23**, **25**, **26--39**, **43--57**, **58--72**, **75--77**, **79--81**, **83**, **84**, **86**, **87**, **89**, **90**, **92**, **93**, **95--97**, **100--104**, **108--110**, **114--116**, **119**, **121**, **122**, and **124**; experimental protocol for the synthesis of the radioligands \[^3^H\]**44** and \[^3^H\]**64**; ^1^H-NMR and ^13^C-NMR spectra of compounds **22**, **25**, **27--29**, **31**, **34**, **35**, **38**, **39**, **43**, **44**, **46**, **48**, **50--52**, **55**, **58--61**, **63**, **64**, **66**, **67**, **69**, **70**, and **72**; RP-HPLC chromatograms of compounds **22**, **25**, **27--29**, **31**, **34**, **35**, **38**, **39**, **43**, **44**, **46**, **48**, **50--52**, **55**, **58--61**, **63**, **64**, **66**, **67**, **69**, **70**, and **72** ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01085/suppl_file/ao7b01085_si_001.pdf))
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ACh

:   acetylcholine

Boc

:   *tert*-butoxycarbonyl

*B*~max~

:   maximum number of binding sites

brs

:   broad singlet

CH~2~Cl~2~

:   dichloromethane

MeCN

:   acetonitrile

CHO-cells

:   Chinese hamster ovary cells

DCC

:   *N*,*N*′-dicyclohexylcarbodiimide

DIPEA

:   diisopropylethylamine

DMAP

:   4-dimethylaminopyridine

dpm

:   disintegrations per minute

EtOAc

:   ethylacetate

GPCR

:   G-protein coupled receptor

HOBt

:   1-hydroxybenzotriazole hydrate

IP1

:   inositol monophosphate

*k*

:   retention (or capacity) factor (HPLC)

*K*~d~

:   dissociation constant obtained from a saturation binding experiment

*K*~i~

:   dissociation constant obtained from a competition binding experiment

*k*~obs~

:   observed rate constant

*k*~off~

:   dissociation rate constant

*k*~on~

:   association rate constant

MR

:   muscarinic receptor

M~*x*~R

:   muscarinic M~*x*~ (*x* = 1--5) receptor

PBS

:   phosphate buffered saline

p*K*~b~

:   negative logarithm of the *K*~b~ (dissociation constant obtained from a functional assay (inhibition of the effect elicited by an agonist)) in M

p*K*~i~

:   negative logarithm of the *K*~i~ in M

SEM

:   standard error of the mean

TBTU

:   2-(1*H*-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium

TFA

:   trifluoroacetic acid

*t*~R~

:   retention time
